{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:49:49Z","timestamp":1789750189719,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to investigate the relationship between autoantibodies, specifically Antinuclear Antibody (ANA) and anti-Sj\u00f6gren\u2019s-syndrome-related antigen A (SSA), and progression-free survival (PFS) in multiple myeloma (MM) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study was conducted on 304 MM patients diagnosed between 2010 and 2020 at Shanghai Changzheng Hospital, with follow-up until October 2023. Patients were stratified based on ANA and SSA positivity. Clinical data were analyzed using Kaplan-Meier survival curves and Cox regression models, adjusting for key prognostic factors. Sensitivity analyses were performed using propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to evaluate the robustness of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SSA-positive patients exhibited significantly shorter PFS compared to SSA-negative patients (17 vs. 44 months, HR = 2.93, 95% CI 1.53-5.64, p = 0.001), while ANA positivity was associated with a smaller increase in risk (HR = 1.57, 95% CI 1.04-2.4, p = 0.034). The impact of SSA remained significant after adjusting for various covariates in the Cox regression model and sensitivity analyses. Subgroup analyses revealed consistent effects of SSA positivity across different demographic and clinical factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SSA positivity is associated with a higher risk of disease progression in MM patients, suggesting it may serve as a valuable prognostic marker. The relationship between autoantibodies and MM prognosis warrants further investigation in larger, multicenter studies to elucidate the underlying mechanisms and inform clinical management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1529678","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:20:59Z","timestamp":1740115259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of ANA and SSA autoantibodies with progression-free survival in multiple myeloma: a retrospective cohort study"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiafeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Van De Donk","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.v106.3","article-title":"Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Baldursd\u00f3ttir","year":"2021","journal-title":"Eur J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbacli.2016.05.004","article-title":"Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"6","author":"Shimanovsky","year":"2016","journal-title":"Bba Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347559","article-title":"Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study","volume":"118","author":"Lindqvist","year":"2011","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0695","article-title":"Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: A systematic review","volume":"23","author":"McShane","year":"2014","journal-title":"Cancer Epidemiology Biomarkers Prev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091461","article-title":"Risk of multiple myeloma in rheumatoid arthritis: A meta-analysis of case-control and cohort studies","volume":"9","author":"Shen","year":"2014","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10238-024-01327-x","article-title":"The casual relationship between autoimmune diseases and multiple myeloma: A mendelian randomization study","volume":"24","author":"Jin","year":"2024","journal-title":"Clin Exp Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3600","article-title":"Facts and hopes in multiple myeloma immunotherapy","volume":"27","author":"Sperling","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2859-8","article-title":"History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study","volume":"96","author":"Lindqvist","year":"2017","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.v11.1","article-title":"Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature review","volume":"11","author":"Lian","year":"2023","journal-title":"Immunity Inflammation Disease"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216287","article-title":"Increased risk of multiple myeloma in primary Sj\u00f6gren\u2019s syndrome is limited to individuals with Ro\/SSA and La\/SSB autoantibodies","volume":"79","author":"Mofors","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncology: Off J Am Soc Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13302-8","article-title":"Essential hypertension","volume":"361","author":"Staessen","year":"2003","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes\u20142010","year":"2010","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04239-2","article-title":"Systemic lupus erythematosus","volume":"357","author":"Ruiz-Irastorza","year":"2001","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren\u2019s syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13317-016-0075-0","article-title":"International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results","volume":"7","author":"Damoiseaux","year":"2016","journal-title":"Autoimmun Highlights"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B26","article-title":"Monoclonal gammapathy of undetermined significance and autoimmune disease: description of three cases in Senegal","volume":"68","author":"Diallo","year":"2008","journal-title":"Med Trop"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/apl.2014.17.issue-6","article-title":"A case series of autoimmune diseases accompanied by incidentally diagnosed monoclonal gammopathy: is there a link between the two diseases","volume":"17","author":"Cho","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103608","DOI":"10.1016\/j.autrev.2024.103608","article-title":"Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop","volume":"23","author":"Andrade","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12967-024-05345-x","article-title":"Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens","volume":"22","author":"Ravn Berg","year":"2024","journal-title":"J Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000347","article-title":"High or low? Assessing disease risk in multiple myeloma","volume":"2022","author":"Schmidt","year":"2022","journal-title":"Hematology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0097","article-title":"Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women","volume":"15","author":"Landgren","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1529678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:21:04Z","timestamp":1740115264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1529678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1529678"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1529678","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"article-number":"1529678"}}